Business Wire

ADVA

Share
Zenlayer uses ADVA FSP 3000 to tackle huge surge in cloud data demand

ADVA (FSE: ADV) today announced that Zenlayer is deploying its FSP 3000 technology to provide dynamic, highly available services to some of the world’s biggest gaming, cloud computing and social media companies. The solution will deliver flexible, ultra-low-latency connectivity, enabling the cloud service provider to address huge bandwidth needs as and when required. This is essential for Zenlayer’s customers that require highly resilient services with dynamic capacity. Built on the compact and scalable ADVA FSP 3000 platform , the new network will carry multiple services, including Ethernet, Fibre Channel and SONET/SDH. For maximum efficiency and elasticity, it also features ADVA’s QuadFlex™ line cards and OpenFabric™ cross-connect technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200602005062/en/

“With this deployment, we’re injecting new levels of flexibility and reliability into our infrastructure. ADVA’s technology offers a major boost to our customers who are delivering more and more data-intensive real-time services to their end users. It opens the door to the next generation of teleconferencing, streaming and online gaming technologies,” said Alex Wang, network architect and product manager, Zenlayer. “Our new solution is extremely efficient in terms of footprint and power consumption. It’s also a future-proof investment ready to scale even further in years to come. Another key component in the success of the project was our close working relationship with ADVA’s engineers. They made sure the whole process was seamless and speedy from network design to shipment and implementation.”

Zenlayer’s new transport network includes some of ADVA’s most innovative technology. Specifically designed for scale and bandwidth optimization, the ADVA FSP 3000 platform ensures that the infrastructure meets the most stringent density and energy demands. Using ADVA FSP 3000 QuadFlex™ technology, the solution delivers outstanding spectral efficiency. The new network also features the ADVA FSP 3000 OpenFabric™ , an OTN cross-connect that creates a distributed architecture, empowering Zenlayer to simply and efficiently adjust bandwidth and turn up new services in an instant. What’s more, for Zenlayer customers such as public cloud and global gaming companies, the solution’s low-latency, high-availability performance will translate directly into end-user satisfaction.

“This deployment will benefit a great number of enterprises operating in Taiwan and Singapore. With the ability to flexibly and efficiently transport multi-traffic services at speeds up to 200Gbit/s, Zenlayer’s telecom, cloud service and gaming customers can enhance the experience of their end users and gain a vital competitive edge,” commented Erik Lindberg, VP, sales, APAC, ADVA. “Zenlayer has a clear vision of what its customers expect and a bold strategy for delivering it. By harnessing our technology and the expertise of our engineers, Zenlayer has created a network ready to adapt to evolving demands and able to expand further in years to come.”

“Our open FSP 3000 technology is the ultimate response to ever-increasing data requirements. It gives Zenlayer the tools it needs to grow its network and develop its edge cloud services in a cost-efficient and highly sustainable way,” said Rocky Weicong Zhou, director, global business development, ADVA. “Combined with our QuadFlex™ and OpenFabric™ technologies, our FSP 3000 platform provides superb levels of capacity and agility. It enables Zenlayer to respond flexibly to huge increases in traffic volume while at the same time making savings on energy use and rack space. With a highly flexible and efficient transport system, Zenlayer can give its enterprise customers world-class connectivity to markets across the globe.”


About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye